ES2664828T3 - Bifidobacterium longum y trastornos GI funcionales - Google Patents

Bifidobacterium longum y trastornos GI funcionales Download PDF

Info

Publication number
ES2664828T3
ES2664828T3 ES09168590.9T ES09168590T ES2664828T3 ES 2664828 T3 ES2664828 T3 ES 2664828T3 ES 09168590 T ES09168590 T ES 09168590T ES 2664828 T3 ES2664828 T3 ES 2664828T3
Authority
ES
Spain
Prior art keywords
functional
bifidobacterium longum
disorders
syndrome
anxiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09168590.9T
Other languages
English (en)
Spanish (es)
Inventor
Peter Mclean
Gabriela Bergonzelli Degonda
Stephen Michael Collins
Premysl Bercik
Elena Verdu De Bercik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41508246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2664828(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Application granted granted Critical
Publication of ES2664828T3 publication Critical patent/ES2664828T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES09168590.9T 2009-08-25 2009-08-25 Bifidobacterium longum y trastornos GI funcionales Active ES2664828T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09168590.9A EP2289527B1 (en) 2009-08-25 2009-08-25 Bifidobacterium longum and functional GI disorders

Publications (1)

Publication Number Publication Date
ES2664828T3 true ES2664828T3 (es) 2018-04-23

Family

ID=41508246

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09168590.9T Active ES2664828T3 (es) 2009-08-25 2009-08-25 Bifidobacterium longum y trastornos GI funcionales

Country Status (17)

Country Link
US (3) US10028981B2 (enExample)
EP (2) EP2289527B1 (enExample)
JP (4) JP2013503130A (enExample)
CN (2) CN102573863A (enExample)
AU (1) AU2010288546B2 (enExample)
BR (1) BR112012004046B1 (enExample)
CA (1) CA2772163C (enExample)
CL (1) CL2012000487A1 (enExample)
DK (1) DK2289527T3 (enExample)
ES (1) ES2664828T3 (enExample)
IN (1) IN2012DN01638A (enExample)
MX (1) MX2012002402A (enExample)
RU (1) RU2012111253A (enExample)
SG (1) SG178499A1 (enExample)
TR (1) TR201807143T4 (enExample)
WO (1) WO2011023689A1 (enExample)
ZA (1) ZA201202155B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
EP2289527B1 (en) 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum and functional GI disorders
EP2452576A1 (en) * 2010-11-11 2012-05-16 Nestec S.A. Extruded non-replicating probiotic micro-organisms and their health benefits
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
MX382895B (es) 2015-06-11 2025-03-13 Soc Des Produits Nestle S A Star Suplemento dietético.
HK1263322A1 (zh) * 2015-08-31 2020-04-17 Société des Produits Nestlé S.A. 使用长双歧杆菌调节情绪反应性并治疗或预防亚临床心境紊乱的方法和组合物
CN107980002A (zh) * 2015-08-31 2018-05-01 雀巢产品技术援助有限公司 使用长双岐杆菌优化母乳喂养的方法和组合物
CN108367033A (zh) * 2015-08-31 2018-08-03 雀巢产品技术援助有限公司 使用长双歧杆菌治疗或预防抑郁症状的方法和组合物
WO2017071715A1 (en) * 2015-10-28 2017-05-04 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
US10780103B2 (en) 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
JP6353478B2 (ja) * 2016-03-28 2018-07-04 日清食品ホールディングス株式会社 セロトニン分泌促進能力を有するビフィズス菌
CN107050062A (zh) * 2016-11-08 2017-08-18 江西益盟科技有限公司 治疗便秘的乳酸菌组合物及其制备方法
CN106579414A (zh) * 2016-12-26 2017-04-26 北京康比特体育科技股份有限公司 一种缓解运动性腹泻的组合物
ES2834950T3 (es) * 2017-02-28 2021-06-21 Prec Group Limited Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmunitaria a la infección por virus respiratorio
EP3589726A1 (en) 2017-02-28 2020-01-08 Alimentary Health Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
EP3618843A1 (en) * 2017-05-05 2020-03-11 Société des Produits Nestlé S.A. Treatment of infant colic
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
US20190298783A1 (en) 2018-03-28 2019-10-03 Morinaga Milk Industry Co., Ltd. Composition for relieving stress, pharmaceutical composition and food and drink composition and method for relieving stress using the composition for relieving stress
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
CN114402062B (zh) * 2019-07-01 2025-02-25 雀巢产品有限公司 产生丝氨酸蛋白酶抑制剂
CN114555635B (zh) 2019-07-01 2024-12-17 雀巢产品有限公司 产生丝氨酸蛋白酶抑制剂
JP2021014421A (ja) * 2019-07-11 2021-02-12 日清ファルマ株式会社 Ｑｏｌ改善剤
JP2021014422A (ja) * 2019-07-11 2021-02-12 日清ファルマ株式会社 便性改善剤
CN111187734A (zh) * 2019-12-25 2020-05-22 生合生物科技（扬州）有限公司 长双歧杆菌bl986、由其制备的冻干粉及冻干粉的应用
EP4117697A1 (en) 2020-03-13 2023-01-18 PrecisionBiotics Group Limited Bifidobacterium longum
EP4449876A3 (en) * 2020-05-20 2025-01-15 Société des Produits Nestlé S.A. Improvement of insoluble fibre fermentability and short chain fatty acid production by bifidobacterium longum
CN115606638A (zh) * 2022-11-07 2023-01-17 内蒙古蒙牛乳业（集团）股份有限公司 一种常温发酵乳制品及其制备方法与应用
WO2026078486A1 (en) * 2024-10-11 2026-04-16 Kolinpharma S.P.A. Composition for the prevention and treatment of intestinal diseases characterised by pain and inflammation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
DE10008279A1 (de) * 2000-02-23 2001-08-30 Meggle Gmbh Milchzucker enthaltende Zusammensetzung
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
EP1429620A1 (en) * 2001-08-31 2004-06-23 Nutricopia, Inc. Nutritional frozen dessert and methods of menufacture
EP1384483A1 (en) 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
JP2004262773A (ja) * 2003-02-17 2004-09-24 Ryoshoku Kenkyukai 免疫機能改善を目的としたビフィズス菌製剤
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
WO2004112507A1 (en) * 2003-06-23 2004-12-29 Nestec S.A. Infant or follow-on formula
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
US8134942B2 (en) * 2005-08-24 2012-03-13 Avaak, Inc. Communication protocol for low-power network applications and a network of sensors using the same
EP1947962B1 (en) * 2005-11-14 2010-10-06 Unilever N.V. Edible product containing ginseng polysaccharides and beneficial bacteria
JP2007169200A (ja) * 2005-12-21 2007-07-05 Morinaga Milk Ind Co Ltd インフルエンザ感染予防のための医薬及び飲食品
AU2007216461B2 (en) * 2006-02-15 2012-08-30 Société des Produits Nestlé S.A. Use of bifidobacterium longum for the prevention and treatment of inflammation
US9005682B2 (en) 2006-03-07 2015-04-14 Nestec S.A. Synbiotic mixture
EP1961308A1 (en) * 2007-02-21 2008-08-27 Nestec S.A. Nutritionally balanced frozen dessert
EP1974735A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Reduction of risk of diarrhoea
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
EP2227239A2 (en) * 2007-12-06 2010-09-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage
BRPI0820802A2 (pt) * 2007-12-17 2015-06-16 Univ Florida Materiais e métodos para tratamento de proliferação vascular ocular patológica
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
WO2010008272A1 (en) * 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
EP2289527B1 (en) 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum and functional GI disorders
DK3745870T3 (da) * 2018-01-29 2023-02-20 Prec Group Limited Et kombinationsprodukt til profylakse og behandling af irritabel tarmsyndrom

Also Published As

Publication number Publication date
CA2772163A1 (en) 2011-03-03
JP7096652B6 (ja) 2022-08-01
CN106072658A (zh) 2016-11-09
BR112012004046B1 (pt) 2021-02-17
AU2010288546A1 (en) 2012-03-22
US11957720B2 (en) 2024-04-16
AU2010288546B2 (en) 2015-08-20
CA2772163C (en) 2017-11-07
EP2470188A1 (en) 2012-07-04
SG178499A1 (en) 2012-04-27
ZA201202155B (en) 2014-09-25
JP2018048112A (ja) 2018-03-29
EP2289527B1 (en) 2018-02-21
JP2020183385A (ja) 2020-11-12
RU2012111253A (ru) 2013-10-10
US20190134104A1 (en) 2019-05-09
TR201807143T4 (tr) 2018-06-21
IN2012DN01638A (enExample) 2015-06-05
EP2289527A1 (en) 2011-03-02
US20220280576A1 (en) 2022-09-08
DK2289527T3 (en) 2018-04-23
US10028981B2 (en) 2018-07-24
BR112012004046A2 (pt) 2017-05-30
CL2012000487A1 (es) 2012-08-31
JP7096652B2 (ja) 2022-07-06
JP2016074682A (ja) 2016-05-12
US11452745B2 (en) 2022-09-27
US20120230956A1 (en) 2012-09-13
WO2011023689A1 (en) 2011-03-03
JP2013503130A (ja) 2013-01-31
CN102573863A (zh) 2012-07-11
MX2012002402A (es) 2012-04-02

Similar Documents

Publication Publication Date Title
ES2545975T3 (es) Composición que contiene piceatannol y procedimiento para producir la composición que contiene piceatannol
ES2477882T3 (es) Probióticos, IgA secretora e infección
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
CO2021015060A2 (es) Agonistas de glp-1r y usos de los mismos
ES2550059T3 (es) Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales
ES2529681T3 (es) Polímeros de colorante
ES2626610T3 (es) Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal
MX2009013293A (es) Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
ES2553593T3 (es) Lixisenatida como complemento de la metformina en el tratamiento de la diabetes tipo 2
CL2018003487A1 (es) Nuevo uso médico de probióticos.
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
CL2012000794A1 (es) Composicion farmaceutica solida de desintegracion oral que comprende 20 mg o menos de un un corticoesteroide y un desintegrador; tableta que se desintegra oralmente; y su uso en el tratamiento de una afeccion inflamatoria del tracto gastrointestinal como inflamacion del esofago, glosis, epiglotis, amigdalas, orofaringea, entre otras.
TR201906881T4 (tr) Hidroklorofluoroolefinlerin bileşimleri.
CO6351785A2 (es) Inhibidores de cinasa map p39
CL2008001170A1 (es) Compuestos derivados de cromanos y naftaleno sustituidos con un anillo heterociclico; composicion farmaceutica; y su uso en el tratamiento del dolor o dolor nociceptivo agudo o cronico, dolor visceral, dolor inflamatorio y/o neuropatico central o periferico.
CL2008001671A1 (es) Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes.
CL2011002739A1 (es) Compuestos derivados de 3-(1h-pirrolo[2,3-b]piridina-3-carbonil)-bencenosulfonamida; composicion farmaceutica que los comprende; kit; y su uso como inhibidores de raf para el tratamiento de una enfermedad o condicion seleccionada de melanoma, glioma, glioblastoma multiforme, cancer colorrectal, cancer de pulmon, entre otras.
MX421305B (es) Probioticos para su uso en el tratamiento de diverticulosis y enfermedad diverticular.
CL2012002904A1 (es) Combinación o composición farmacéutica que comprende un inhibidor de la señalización de células y/o de la angiogénesis y un inhibidor de la quinasa aurora (aki); kit faramcéutico que la comprende; su uso en el tratamiento de enfermedades oncológicas y fibróticas; y compuestos derivados de indol y pirimidina sustituidos.
CL2017002826A1 (es) Cepa bacteriana que reduce la señalización del dolor y altera la motilidad gastrointestinal; composición que la comprende; uso de dicha composición para tratar la constipación o cólicos; uso de dicha composición para tratar o reducir el riesgo de desarrollar síndrome del intestino irritable.(solicitud divisional 490-2015)
GT200600125A (es) Nueva sal y polimorfos del inhibidor de la dpp-iv
CL2012000487A1 (es) Composicion que comprende bifidobacterium longum baa-999 para tratar y/o prevenir trastornos gi funcionales.
CL2011002597A1 (es) Compuestos derivados de rifamicina; procedimiento de preparacion; composicion farmaceutica; su uso para tratar, prevenir o aliviar sobrecrecimiento bacteriano en trastornos intestinales tales como sindrome de colon irritable, diarrea del viajante, enfermedad de crohn, encefalopatia hepatica y enteritis.
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
ES2531516T3 (es) Uso de escina